ArticleFrontiers in cardiovascular medicine2023
Single center experience and early outcomes of Impella 5.5.
Article in Frontiers in cardiovascular medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.
- Concurrent Use of Kidney Replacement Therapy and Temporary Left Ventricular Assist Device in Cardiogenic Shock: A Systematic Review and Meta-Analysis.Blood purification · 2025Pooled it
- Rapid Treatment of Acute Decompensated Heart Failure with Cardiogenic Shock in the Emergency Setting.Cardiology and cardiovascular medicine · 2026Article
- Incidence and clinical outcomes of extended duration support in patients with Impella 5.5 - Analysis from the LOQI Registry.JHLT open · 2026Article
- Impella 5.5 Support in Severe Cardiogenic Shock: Outcomes From the First Spanish Multicentre Cohort in Heart Transplant Centres.Interdisciplinary cardiovascular and thoracic surgery · 2026Observational
- Anticoagulation with bivalirudin is associated with improved biocompatibility in patients supported on microaxial flow pumps.JTCVS open · 2026Article
- Experts' recommendations for the management of adult patients with cardiogenic shock.Annals of intensive care · 2026Article
- Perioperative temporary microaxial left ventricular assist device support in patients with low ejection fraction undergoing coronary artery bypass grafting.Frontiers in cardiovascular medicine · 2026Article
- Clinical outcomes of Impella 5+ in acute myocardial infarction-related cardiogenic shock: a retrospective single-center study.Frontiers in cardiovascular medicine · 2026Article
- Mortality Predictors in Short-Term Mechanical Circulatory Support as a Bridge to Heart Transplantation.Biomedicines · 2025Article
- Surgically implanted temporary ventricular assist pump - "Impella 5.5".Indian journal of thoracic and cardiovascular surgery · 2025Review
- Mechanical circulatory support as a cornerstone in advanced heart failure and transplantation.Frontiers in cardiovascular medicine · 2025Review
- Trajectories following Impella 5.5 support are associated with initial presentation acuity.Artificial organs · 2025Article
- Are there etiology-specific risk factors for adverse outcomes in patients on Impella 5.5 support?JTCVS open · 2024Article
- Impella 5.5 Use in the Setting of Severe Aortic Insufficiency: A Relative Contraindication.Annals of thoracic surgery short reports · 2024Article
- Prolonged Impella 5.0/5.5 support within different pathways of care for cardiogenic shock: the experience of a referral center.Frontiers in cardiovascular medicine · 2024Article
- An explainable machine learning approach using contemporary UNOS data to identify patients who fail to bridge to heart transplantation.Frontiers in cardiovascular medicine · 2024Article
- Cardiogenic shock etiology and exit strategy impact survival in patients with Impella 5.5.The International journal of artificial organs · 2024Article
- Short-term mechanical support with the Impella 5.x for mitral valve surgery in advanced heart failure-protected cardiac surgery.Frontiers in cardiovascular medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Acute decompensated heart failure (HF) and cardiogenic shock (CS) frequently are refractory to conservative treatment and require mechanical circulatory support (MCS). We report our early clinical experience and evaluate patient outcomes with the newer generation surgical Impella 5.5. Methods: Seventy patients that underwent Impella 5.5 implantation between October 2019 and December 2021 at a single center were enrolled in this study. Pre-operative characteristics, peri-operative clinical course information, and post-operative outcomes were retrospectively collected. Results: Fifty-seven (81%) patients survived to discharge, and 51 (76%) patients survived at the time of the first 30 days post-discharge visit. Thirty-one patients (44%) received Impella support for a bridge to advanced surgical heart failure therapy (transplant or durable left ventricular assist device [LVAD]), 27 (39%) cases were used for a bridge to recovery/decision and 12 (17.1%) cases was used for planned perioperative support for high-risk cardiac surgery procedure. Conclusion: Our results suggest that Impella 5.5 provides favorable survival in the management of HF and CS, particularly used for a bridge to heart transplant or LVAD. Early extubation and mobilization with high flow circulatory support allowed effective tailoring of MCS approaches from peri-operative support for high-risk cardiac surgery, bridge to recovery, and to advanced surgical heart failure therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.